Posted Tuesday April 7, 2020


COVID-19 convalescent plasma for patients

Canadian Blood Services to participate in national clinical trial

Canadian Blood Services is actively working with Health Canada and the international research community to contribute to the global effort to determine if COVID-19 convalescent plasma could be an effective treatment for the coronavirus.

Canadian Blood Services is part of a team of experts representing Canada on an international working group in partnership with Australia, China, France, Germany, Italy, Singapore, South Korea, the Netherlands, the United Kingdom and the United States.

In Canada, the research community has rallied together to design a national clinical trial on the use of convalescent plasma in treating the virus. An application will be submitted to Health Canada shortly. Pending approval, Canadian Blood Services and Héma-Québec will be responsible for supplying convalescent plasma to hospitals across the country.

“We have the expertise and the infrastructure necessary to collect and prepare convalescent plasma for use in a clinical trial to test its safety and effectiveness as a treatment option,” said Dr. Dana Devine, chief scientist for Canadian Blood Services. “Plasma will only be collected from volunteer donors who have fully recovered from the virus and will be used by Canadian physicians caring for patients with COVID-19 in the context of the clinical trial.”

Once the trial is underway, Canadian Blood Services will contact potential convalescent plasma donors based on defined criteria which will be approved as part of the clinical trial protocol. Convalescent plasma donors will also need to meet current Canadian Blood Services’ donor eligibility criteria. Presently, there is a small, but growing, number of people across Canada who could be eligible to participate as convalescent plasma donors in this trial.

Convalescent plasma is collected through the plasma donation process. When someone contracts a virus, their body develops antibodies against it. The antibodies remain present in their plasma to shield them from possible future infection. In theory, these antibodies could be the key ingredient for a treatment to help others with the same virus.

 is distributed twice weekly; Tuesday and Thursday

Not a Subscriber? Receive more articles on business issues
Sent directly to your email in-box.

contact us

Publisher is Exchange Business Communication Inc.
Email Publisher

ISSN 0824-45
Copyright, 2020

Share Your Story: pressrelease @
Expand Your Reach:
advertise @
Publisher: Exchange Business Communication Inc., PO Box 248, Waterloo, Ontario, Canada
Email Editor

Content published on this site represents the opinion of the individual, organization and/or source provider. is a online daily journal of Exchange Business Communication Inc. (1997) Publishers of Exchange Magazine est. 1983. Privacy Policy. Copyright of Exchange produced editorial is the copyright of Exchange Business Communications Inc. 2020. Submitted editorials, comments and releases are copyright of respective source(s).